Feb 26, 2026DOI: 10.1056/nejmoa2506495Original ArticleNEJM
Written by: Jason Zucker, M.D.William A. Fischer, M.D.Lu Zheng, Ph.D.Caitlyn McCarthy, M.A.Pooja T. Saha, Ph.D.Arzhang Cyrus Javan, M.D.Alex Greninger, M.D.Matthew M. Hamill, M.B., Ch.B.Kieron Leslie, M.D.Kristina M. Brooks, Pharm.D.Jonathan Berardi, F.N.P.Davey Smith, M.D.Lara Hosey, M.A.Grace Aldrovandi, M.D.Kathie Ferbas, Ph.D.Cheryl Day, Ph.D.Rachel A. Bender Ignacio, M.D.Robert Bolan, M.D.Marshall J. Glesby, M.D.Raphael J. Landovitz, M.D.Anne F. Luetkemeyer, M.D.Juan Sierra Madero, M.D.Rajesh T. Gandhi, M.D.Sharon Nachman, M.D.Joe Eron, M.D.Judith S. Currier, M.D.Timothy Wilkin, M.D.
Find these authors on Roon
RB
Dr. Rachel Bender Ignacio
HIV/AIDS Medicine · UW / Fred Hutch
RL
Dr. Raphael J. Landovitz
HIV/AIDS Medicine · UCLA
[Free Article]
Summary
Mpox continues to spread in many communities. Tecovirimat has activity against orthopoxviruses in vitro. In a phase 3 trial involving patients with acute mpox, tecovirimat showed no evidence of clinical activity.
RL
Dr. Raphael J. Landovitz
Infectious Disease · HIV & AIDS MedicineUniversity of California, Los AngelesraphaellLos Angeles, CA, USA